From an early age, they were both fascinated by science; he was amazed by advances in genetic engineering, and she was learning everything she could about plants. Fast forward to today, , Assistant Professor of Radiation Oncology and Biochemistry and Biophysics, and , Assistant Professor of Immunology, are using their natural curiosity and drive to tackle the problem of cancer.
Pylayeva-Gupta is studying how to boost the immune system鈥檚 ability to respond and fight pancreatic cancer. Gupta is a physician-scientist working in the clinic and researching cancer genetics in the laboratory.
Yuliya Pylayeva-Gupta, PhD, and Gaorav Gupta, MD, PhD, are planning a project that will combine their expertise in radiation, biochemistry, and immunotherapy.
Pylayeva-Gupta was born in Azerbaijan and immigrated to the United States before college. She had a natural interest in problem solving, and cancer was the most complex problem she knew of in biology. Gupta grew up in Chicago and found his calling during a summer internship at the National Cancer Institute as an undergraduate studying at the University of Chicago.
They met during graduate school at Weill Cornell Medicine in New York. After they completed their training, they accepted positions at 黑料网 Lineberger because they found the cancer center valued all aspects of their research and offered a nurturing, collaborative environment.
鈥淲hat they were primarily interested in was excellent cancer science, and they saw what we were doing and valued each of us independently,鈥� Gupta said.
Gaorav鈥檚 work in breast cancer and HPV-linked head and neck cancer research
It was soon after they started dating in graduate school that Gupta had one of his biggest breakthroughs. Pylayeva-Gupta had left for a trip abroad, and Gupta worked into the early hours of the morning to distract himself from her absence.
While he was poring through his data, he that can cause the cancer to metastasize, or spread. The .
At 黑料网 Lineberger, Gupta is working on an experimental . He is also studying how DNA becomes abnormal and unstable in cancer.
鈥淲e鈥檙e beginning to unravel new ways in which DNA in cancer is altered, and I鈥檓 very excited about the prospect that this may lead to new opportunities to take advantage of those abnormalities for therapeutic benefit,鈥� he said.